The company has voluntarily stopped enrolling new patients in the studies in response to reports of mostly mild or moderate ...

Bristol Myers Squibb has axed the degrader-antibody conjugate (DAC) it bought from Orum Therapeutics for $100 million, ...

A new biotech has sprung out of stealth with a bold vision to develop the “greatest therapeutic of all time”—a drug that can ...

Prediction markets are opening up new ways to bet on biopharma events, from clinical trial readouts to FDA approvals. | In this episode of “The Top Line,” we explore the growing space of biopharma ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Electra Therapeutics is the latest biotech to overshoot its own IPO expectations this year, with the inflammation-focused company bringing in $350 million from this morning’s Nasdaq listing. | Electra ...

North Immunology has decided its path to taking its atopic dermatitis (AD) drug into the clinic involves going public via a ...

Novo’s race to rejuvenate its cardiometabolic portfolio has seen the rebranded Danish pharma pen a $1.4 biobucks pact with ...

A rare inherited germline mutation was found to increase risk for lung cancer by 25 times, while smoking only increased risk by 4 times.

Lisata began hunting for an exit after a planned merger with Kuva Labs fell apart last month, which led the company to lay off 72% of its workforce, including its chief medical officer. Kuva had ...

Novartis has extended its losing streak, stopping an amyotrophic lateral sclerosis (ALS) program after flunking a phase 2 ...

A phase 2b study of Longeveron’s stem cell therapy in a pediatric heart disease has missed its primary endpoint, prompting ...